Recombinant protein corresponding to Thr20-Leu1639 of mouse Siglec-1, expressed in NS0 cells
Siglec-1, also known as sialoadhesin or CD169, is a 175-185kD type I transmembrane glycoprotein belonging to the Siglec family of sialic acid specific I-type lectins within the immunoglobulin superfamily. Mouse Siglec-1 contains a 1619 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set domain and 16 Ig-like C2-set domains. The ECD shares 73% and 83% aa sequence identity with human and rat Siglec-1, respectively. Alternate splicing generates two soluble isoforms containing either 16 or the first 3 Ig-like domains. Siglec-1 is expressed by some tissue macrophages, dendritic cells and circulating monocytes during certain infections. It binds sialylated molecules including MMR, MGL1/CD301a, MUC1, PSGL-1 and CD43. Applications: Suitable for use in Neutralization and Western Blot. Other applications not tested. Recommended Dilutions: Neutralization: Measured by its ability to neutralize Siglec-1/CD169-mediated adhesion of human red blood cells (1). The Neutralization Dose (ND50) is typically 1-5ug/mL in the presence of 5ug/ml recombinant mouse Siglec-1/CD169 Fc Chimera. Western Blot: 1ug/ml. Tested with lysates of mouse lymph node tissue Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized and reconstituted products are stable for 12 months after receipt at -20C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
